Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Anti-Hu antibody titre and brain metastases before and after treatment forsmall cell lung cancer
Autore:
Verschuuren, JJ; Perquin, M; ten Velde, G; De Baets, M; Vriesman, PV; Twijnstra, A;
Indirizzi:
Leiden Univ, Med Ctr, Dept Neurol, NL-2300 RC Leiden, Netherlands Leiden Univ Leiden Netherlands NL-2300 RC NL-2300 RC Leiden, Netherlands Univ Maastricht, Dept Neurol, Maastricht, Netherlands Univ Maastricht Maastricht Netherlands Neurol, Maastricht, Netherlands Univ Maastricht, Dept Pulmonol, Maastricht, Netherlands Univ Maastricht Maastricht Netherlands ulmonol, Maastricht, Netherlands Univ Maastricht, Dept Immunol, Maastricht, Netherlands Univ Maastricht Maastricht Netherlands Immunol, Maastricht, Netherlands
Titolo Testata:
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
fascicolo: 3, volume: 67, anno: 1999,
pagine: 353 - 357
SICI:
0022-3050(199909)67:3<353:AATABM>2.0.ZU;2-D
Fonte:
ISI
Lingua:
ENG
Soggetto:
PARANEOPLASTIC ENCEPHALOMYELITIS; PROGNOSTIC FACTORS; IMPROVED SURVIVAL; ASSOCIATION; CARCINOMA;
Keywords:
small cell lung cancer; anti-Hu antibody; metastases;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
11
Recensione:
Indirizzi per estratti:
Indirizzo: Verschuuren, JJ Leiden Univ, Med Ctr, Dept Neurol, POB 9600, NL-2300 RC Leiden, Netherlands Leiden Univ POB 9600 Leiden Netherlands NL-2300 RC rlands
Citazione:
J.J. Verschuuren et al., "Anti-Hu antibody titre and brain metastases before and after treatment forsmall cell lung cancer", J NE NE PSY, 67(3), 1999, pp. 353-357

Abstract

Objectives-To follow up the level of anti-Hu antibody titres during chemotherapy and to compare the pattern of metastases and other neurological complications before and after chemotherapy in patients with small cell lung cancer (SCLC) with and without low titre anti-Hu antibodies. Seventeen per cent of patients with SCLC without paraneoplastic syndromes have a low titre of anti-Hu antibodies in their serum. Previous studies suggested that theseantibodies correlate with a more indolent tumour growth. Methods-The serum of 52 consecutive patients with SCLC were studied beforeand during chemotherapy, and the correlation with stage of disease and pattern of metastases was examined. All serum samples were investigated using western blot and enzyme linked immunosorbent assay (ELISA) with HuD recombinant protein. All patients with SCLC were investigated using MRI of the brain, CSF, bone marrow aspiration, ultrasound of the abdomen, and radionuclide bone scan. Results-Nine (17%) of 52 SCLC serum samples were positive by western blot. At the time of diagnosis none of the anti-Hu positive patients had either CNS (brain or leptomeningeal), epidural, adrenal, or bone marrow metastasesand 56% had limited disease. In eight of 43 anti-Hu negative patients CNS metastases were found at the time of diagnosis, and only 30% had limited disease. The prevalence of bone and Liver metastases was similar in both groups. Survival was 11 (SD) months for the 43 anti-Hu negative and 10 (SD 6) months for the nine anti-Hu positive patients. Male:female ratio in the anti-Hu negative group was 4.4:1, and in the anti-Hu positive group 2:1. Conclusions-No anti-Hu antibody positive serum, as tested by western blot,became negative during chemotherapy. Anti-Hu positive and anti-Hu negativepatients had similar survival, but anti-Hu positive patients tended to be women, had limited disease at the time of tumour diagnosis, and initially metastases seemed to spare the nervous system.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 05/12/20 alle ore 13:56:16